

09/9/0388

142

**THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS**

**Abstract of the Disclosure**

Methods are provided for inhibiting stenosis following  
5 vascular trauma or disease in a mammalian host, comprising  
administering to the host a therapeutically effective dosage  
of a therapeutic conjugate containing a vascular smooth muscle  
binding protein that associates in a specific manner with a  
cell surface of the vascular smooth muscle cell, coupled to  
10 a therapeutic agent dosage form that inhibits a cellular  
activity of the muscle cell. Methods are also provided for  
the direct and/or targeted delivery of therapeutic agents to  
vascular smooth muscle cells that cause a dilation and  
fixation of the vascular lumen by inhibiting smooth muscle  
15 cell contraction, thereby constituting a biological stent.  
Also discussed are mechanisms for in vivo vascular smooth  
muscle cell proliferation modulation, agents that impact those  
mechanisms and protocols for the use of those agents.

"Express Mail" mailing label number: EL67164114US

Date of Deposit: July 20, 2001

This paper or fee is being deposited on the date indicated above with  
the United States Postal Service pursuant to 37 CFR 1.10, and is  
addressed to the Commissioner for Patents, Box Patent Application,  
Washington, D.C. 20231.